Premium
Advancements in MAPK signaling pathways and MAPK ‐targeted therapies for ameloblastoma: A review
Author(s) -
You Zhu,
Liu ShaoPeng,
Du Jing,
Wu YiHua,
Zhang ShiZhou
Publication year - 2019
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12807
Subject(s) - mapk/erk pathway , signal transduction , protein kinase a , targeted therapy , kinase , biology , cancer research , microbiology and biotechnology , bioinformatics , cancer , genetics
Numerous signal transduction pathways are closely associated with the occurrence, development, and prognosis of ameloblastoma ( AM ). Mitogen‐activated protein kinase ( MAPK ) is a serine/threonine‐specific protein kinase that transduces intracellular signals in critical cellular phenomena. A number of recent analyses have reported that the MAPK signaling pathway contributes significantly to AM . High‐throughput DNA sequencing methods, such as next‐generation sequencing using Illumina have yielded advancements in studies on MAPK signaling pathways and their association with AM ; in particular, BRAF V600E is mediated by the activation of the Ras/Raf/ MAPK pathway. This review discusses advancements in studies on MAPK signaling pathways and MAPK ‐targeted inhibitors or antibodies, along with the merits and demerits of MAPK ‐targeted therapies, finally followed by a discussion regarding more efficient potential MAPK ‐targeted therapies to treat AM with few side effects, thereby providing novel insights into targeted therapy for AM .